Lexicon Pharmaceuticals LXRX shares plummeted after the company received a written notice from Sanofi SNY terminating the agreement for the development and commercialization of the company's Diabetes drug candidate Sotagliflozin.
Lexicon Pharmaceuticals shares were trading were trading down 47.45% at $2.99 in Monday’s pre-market session. The stock has a 52-week high of $12.95 and a 52-week low of $4.25.
Sanofi shares were trading up 2.34% at $43.35 in Monday’s pre-market session. The stock has a 52-week high of $45.62 and a 52-week low of $40.19.
Related Links:
Sanofi, Google Partner On Health Care-Focused Virtual Innovation Lab
Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
